Annovis Stock Story

ANVS -  USA Stock  

USD 21.62  1.36  5.92%

Biocardia would recover faster from the current slip as its shares price went up 2.98% to Annovis Bio's 9.15%As many of us are excited about healthcare space, we will review both, Annovis Bio and Biocardia as a potential short-term opportunity. We are going to discuss some of the competitive aspects of both Annovis and Biocardia.
Published over a month ago
View all stories for Annovis Bio | View All Stories
Is Biocardia more volatile than Annovis Bio (NYSEMKT:ANVS)?
By analyzing existing basic indicators between Annovis Bio and Biocardia, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Biocardia with a short position in Annovis Bio. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Annovis Bio has an asset utilization ratio of 19.04 percent. This connotes that the company is making $0.19 for each dollar of assets. An increasing asset utilization means that Annovis Bio is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Annovis or Brickell is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Annovis Bio's Liquidity

Annovis Bio financial leverage refers to using borrowed capital as a funding source to finance Annovis Bio ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Annovis Bio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Annovis Bio's total debt and its cash.

Correlation Between Annovis and Brickell Biotech

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Annovis Bio together with similar or unrelated positions with a negative correlation. For example, you can also add Brickell Biotech to your portfolio. If Brickell Biotech is not perfectly correlated to Annovis Bio it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Annovis Bio for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Please check pair correlation details between ANVS and BBI for more information.


Are you currently holding both Annovis Bio and Brickell Biotech in your portfolio?
Please note if you are using this as a pair-trade strategy between Annovis Bio and Brickell Biotech, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses.

Another angle On Annovis Bio

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Now, let's check Annovis Bio revenue. Based on the latest financial disclosure, Annovis Bio reported 366.66 K of revenue. This is 100.0% lower than that of the Healthcare sector and 99.95% lower than that of the Biotechnology industry. The revenue for all United States stocks is 100.0% higher than that of Annovis Bio. As for Biocardia we see revenue of 195 K, which is 99.97% lower than that of the Biotechnology

742.9 M
Sector742.91 Million99.92

Time to exit of Annovis Bio?

Latest potential upside is at 12.04. Annovis Bio is displaying above-average volatility over the selected time horizon. Investors should scrutinize Annovis Bio independently to ensure intended market timing strategies are aligned with expectations about Annovis Bio volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Annovis Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Annovis Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Annovis Bio

While few other entities in the biotechnology industry are either recovering or due for a correction, Annovis may not be as strong as the others in terms of longer-term growth potentials. In closing, as of the 16th of October 2021, we believe that at this point, Annovis Bio is undervalued with very high odds of financial distress within the next 2 years. Our latest buy-or-sell advice on the enterprise is Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Annovis Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to